Short answer
Cartesian Therapeutics, Inc. (RNAC) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $0 with net income of $16M.
Q2 2026 key financials · XBRL
- Revenue
- $0
- Net income
- $16M
- −0.7% YoY · +140.2% QoQ
- EPS (diluted)
- $0.63
- +3.3% YoY · +143.2% QoQ
Source: XBRL data from the Cartesian Therapeutics, Inc. (RNAC) Q2 2026 10-Q on SEC EDGAR. USD.
Cartesian Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0 vs $0.3M, down 100% YoY
- Net income $15.8M vs $15.9M; operating margin -NM due to $29.2M operating loss
- Descartes-08 MG R&D $12.5M, up 148% YoY; worst line early-stage programs $1.0M, down 43%
- Cash, equivalents and restricted cash $149.3M at June 30, 2026, including $1.7M restricted cash
- $50.0M first-tranche debt funded; ongoing losses and higher R&D expected to require additional capital
Risk Factors
- New debt risk triggered by May 2026 Loan Agreement with K2HV, secured by substantially all assets except intellectual property
- Most material update: minimum unrestricted cash requirement begins April 1, 2027 at 80% of outstanding obligations
- Regulatory or compliance risk: trailing three-month net product revenue covenant of $40.0 million begins January 1, 2029
- Operational risk: restrictive debt covenants limit additional indebtedness, acquisitions, investments, and asset sales
- Financial risk: equity or convertible debt issuance could dilute stockholder ownership and depress common-stock value
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cartesian Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.